Top

Published in:

01-06-2014 | Review

Invasion and metastasis of renal cell carcinoma

Authors: Shuji Mikami, Mototsugu Oya, Ryuichi Mizuno, Takeo Kosaka, Ken-ichi Katsube, Yasunori Okada

Published in: Medical Molecular Morphology | Issue 2/2014

Abstract

Renal cell carcinoma (RCC) represents over 80 % of kidney cancer, and about 30 % of the patients with RCC develop metastasis after the surgery. Invasion of basement membrane (BM) and extracellular matrix (ECM) is an essential event in tumor invasion and metastasis. Matrix metalloproteinases (MMPs), which digest the main components of BM and ECM, are expressed in RCC. Heparanase, which degrades heparan sulfate proteoglycans, is predominantly expressed in high-grade RCCs with a positive correlation with pathological tumor stage and poor prognosis. Bone metastasis is common among the patients with RCC, and increased osteoclastic activity was observed at metastatic sites. Receptor activator of nuclear factor κB ligand (RANKL), which plays an important role in osteoclastogenesis, is predominantly expressed in high-grade RCC and its expression level is associated with bone metastasis and prognosis. Epithelial-mesenchymal transition (EMT), a switch of epithelial cells to sarcomatoid phenotype, is considered to be critical step during metastasis, and Snail, a major regulator of EMT, is predominantly expressed in high-grade RCC, and high Snail expression is a worse prognostic factor. Accordingly, heparanase, RANKL and Snail may be targets for the development of anti-tumor therapies for RCCs.

Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds) (2005) World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. IARC Press, Lyon

Jung K, Lein M, Laube C, Lichtinghagen R (2001) Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 314:241–244PubMedCrossRef

Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663PubMedCrossRef

Jung K, Nowak L, Lein M, Priem F, Schnorr D, Loening SA (1997) Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer. Int J Cancer 74:220–223PubMedCrossRef

Janzen NK, Kim HL, Figlin RA, Belldegrun AS (2003) Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30:843–852PubMedCrossRef

Suzuki K, Mizuno R, Mikami S, Tanaka N, Kanao K, Kikuchi E, Miyajima A, Nakagawa K, Oya M (2012) Prognostic significance of high nuclear grade in patients with pathologic T1a renal cell carcinoma. Jpn J Clin Oncol 42:831–835PubMedCrossRef

Eccles SA (1999) Heparanase: breaking down barriers in tumors. Nat Med 5:735–736PubMedCrossRef

Engbring JA, Kleinman HK (2003) The basement membrane matrix in malignancy. J Pathol 200:465–470PubMedCrossRef

Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260–1270PubMedCrossRef

10.

Curran S, Murray GI (2000) Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 36:1621–1630PubMedCrossRef

11.

Shiomi T, Lemaitre V, D’Armiento J, Okada Y (2010) Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases. Pathol Int 60:477–496PubMedCentralPubMedCrossRef

12.

Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun HJ, Ringert RH (1998) Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 160:1914–1918PubMedCrossRef

13.

Lein M, Jung K, Laube C, Hubner T, Winkelmann B, Stephan C, Hauptmann S, Rudolph B, Schnorr D, Loening SA (2000) Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. Int J Cancer 85:801–804PubMedCrossRef

14.

Vlodavsky I, Beckhove P, Lerner I, Pisano C, Meirovitz A, Ilan N, Elkin M (2012) Significance of heparanase in cancer and inflammation. Cancer Microenviron 5:115–832PubMedCentralPubMedCrossRef

15.

Nakajima M, Irimura T, Di Ferrante N, Nicolson GL (1984) Metastatic melanoma cell heparanase. Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase. J Biol Chem 259:2283–2290PubMed

16.

Dall’Oglio MF, Ribeiro-Filho LA, Antunes AA, Crippa A, Nesrallah L, Goncalves PD, Leite KR, Srougi M (2007) Microvascular tumor invasion, tumor size and Fuhrman grade: a pathological triad for prognostic evaluation of renal cell carcinoma. J Urol 178:425–428PubMedCrossRef

17.

Mikami S, Oya M, Shimoda M, Mizuno R, Ishida M, Kosaka T, Mukai M, Nakajima M, Okada Y (2008) Expression of heparanase in renal cell carcinomas: implications for tumor invasion and prognosis. Clin Cancer Res 14:6055–6061PubMedCrossRef

18.

Zekri J, Ahmed N, Coleman RE, Hancock BW (2001) The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 19:379–382PubMed

19.

Dougall WC (2012) Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clin Cancer Res 18:326–335PubMedCrossRef

20.

Wittrant Y, Theoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D, Redini F (2004) RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 1704:49–57PubMed

21.

Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET (2003) Soluble receptor activator of nuclear factor κB Fc diminishes prostate cancer progression in bone. Cancer Res 63:7883–7890PubMed

22.

Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, Khokha R, Wada T, Penninger JM (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440:692–696PubMedCrossRef

23.

Wittrant Y, Lamoureux F, Mori K, Riet A, Kamijo A, Heymann D, Redini F (2006) RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol 28:261–269PubMed

24.

Mikami S, Katsube K, Oya M, Ishida M, Kosaka T, Mizuno R, Mochizuki S, Ikeda T, Mukai M, Okada Y (2009) Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J Pathol 218:530–539PubMedCrossRef

25.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 48:3082–3092PubMedCrossRef

26.

Keizman D, Ish-Shalom M, Maimon N, Gottfried M (2013) Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases? World J Urol (in press)

27.

Kijima T, Fujii Y, Suyama T, Okubo Y, Yamamoto S, Masuda H, Yonese J, Fukui I (2009) Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int 103:620–624PubMedCrossRef

28.

Nieto MA (2011) The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 27:347–376PubMedCrossRef

29.

Grunert S, Jechlinger M, Beug H (2003) Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 4:657–665PubMedCrossRef

30.

Canel M, Serrels A, Frame MC, Brunton VG (2013) E-cadherin-integrin crosstalk in cancer invasion and metastasis. J Cell Sci 126:393–401PubMedCrossRef

31.

Thiery JP (2003) Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15:740–746PubMedCrossRef

32.

Alves CC, Carneiro F, Hoefler H, Becker KF (2009) Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. Front Biosci 14:3035–3050CrossRef

33.

Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, Garcia De Herreros A (2000) The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2:84–89PubMedCrossRef

34.

Katagiri A, Watanabe R, Tomita Y (1995) E-cadherin expression in renal cell cancer and its significance in metastasis and survival. Br J Cancer 71:376–379PubMedCentralPubMedCrossRef

35.

Esteban MA, Tran MG, Harten SK, Hill P, Castellanos MC, Chandra A, Raval R, O’Brien TS, Maxwell PH (2006) Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 66:3567–3575PubMedCrossRef

36.

Evans AJ, Russell RC, Roche O, Burry TN, Fish JE, Chow VW, Kim WY, Saravanan A, Maynard MA, Gervais ML, Sufan RI, Roberts AM, Wilson LA, Betten M, Vandewalle C, Berx G, Marsden PA, Irwin MS, Teh BT, Jewett MA, Ohh M (2007) VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol 27:157–169PubMedCentralPubMedCrossRef

37.

Harten SK, Shukla D, Barod R, Hergovich A, Balda MS, Matter K, Esteban MA, Maxwell PH (2009) Regulation of renal epithelial tight junctions by the von Hippel–Lindau tumor suppressor gene involves occludin and claudin 1 and is independent of E-cadherin. Mol Biol Cell 20:1089–1101PubMedCentralPubMedCrossRef

38.

Mikami S, Katsube K, Oya M, Ishida M, Kosaka T, Mizuno R, Mukai M, Okada Y (2011) Expression of Snail and Slug in renal cell carcinoma: E-cadherin repressor Snail is associated with cancer invasion and prognosis. Lab Invest 91:1443–1458PubMedCrossRef

Title: Invasion and metastasis of renal cell carcinoma
Authors: Shuji Mikami
Mototsugu Oya
Ryuichi Mizuno
Takeo Kosaka
Ken-ichi Katsube
Yasunori Okada
Publication date: 01-06-2014
Publisher: Springer Japan
Published in: Medical Molecular Morphology / Issue 2/2014
Print ISSN: 1860-1480
Electronic ISSN: 1860-1499
DOI: https://doi.org/10.1007/s00795-013-0064-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Invasion and metastasis of renal cell carcinoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Aquaporin-1 is associated with arterial capillary proliferation and hepatic sinusoidal transformation contributing to portal hypertension in primary biliary cirrhosis

Recent classification of renal epithelial tumors

Characteristic patterns of maternal and fetal arterial construction in the rabbit placenta

Diamine oxidase as a marker of intestinal mucosal injury and the effect of soluble dietary fiber on gastrointestinal tract toxicity after intravenous 5-fluorouracil treatment in rats

Platelet-rich plasma releasate promotes angiogenesis in vitro and in vivo

Exceptionally large solitary fibrous tumor arising from the cheek: an immunohistochemical and ultrastructural study with a review of the literature